Exacerbation severity and frequency are crucial for the prognosis of COPD, but also appear to have a major impact on the course of comorbidities. There is a growing body of evidence showing that COPD patients are at increased risk of cardiovascular events, with the frequency and severity of exacerbations being important predictors. Optimal treatment of COPD also appears to reduce the risk of concomitant diseases. Depending on the situation, it may make sense to extend dual bronchodilation with inhaled steroids or roflumilast as an add-on.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Colorectal Cancer
Insulin Resistance, Obesity, and Progression
- Modern asthma therapies
New data on biologics and triple therapy
- From symptom to diagnosis
Abdominal Pain – Focal Nodular Hyperplasia
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Hepatology and Metabolism
The Mediterranean Diet for MASLD/MASH—What the EASL-EASD-EASO Guidelines Specifically Recommend
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?